We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+18.72%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$512M
AUM Growth
-$81.4M
Cap. Flow
-$45M
Cap. Flow %
-8.79%
Top 10 Hldgs %
73.66%
Holding
32
New
4
Increased
5
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$45M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$16.6M
3
COGT icon
Cogent Biosciences
COGT
+$10.8M
4
PLRX icon
Pliant Therapeutics
PLRX
+$9.96M
5
FULC icon
Fulcrum Therapeutics
FULC
+$7.7M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$51.7M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$44.7M
3
NVAX icon
Novavax
NVAX
+$19.3M
4
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$11.8M
5
LIAN
LianBio American Depositary Shares
LIAN
+$7.86M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRDN icon
1
Viridian Therapeutics
VRDN
$2.09B
$68.7M 13.41%
2,699,865
– –
COGT icon
2
Cogent Biosciences
COGT
$6.65B
$52.7M 10.29%
4,884,977
+846,860
+21% +$10.8M
ELVN icon
3
Enliven Therapeutics
ELVN
$3.92B
$48.5M 9.47%
+2,214,142
New +$45M
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$42.9M 8.37%
3,619,522
-88,369
-2% -$844K
PLRX icon
5
Pliant Therapeutics
PLRX
$64.4M
$38M 7.43%
1,430,000
+350,000
+32% +$9.96M
AMAM
6
DELISTED
Ambrx Biopharma Inc
AMAM
$29.4M 5.74%
+3,298,577
New +$16.6M
GHRS icon
7
GH Research
GHRS
$1.93B
$28.1M 5.49%
3,517,125
– –
DICE
8
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$23.5M 4.58%
819,000
– –
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$22.9M 4.48%
2,916,667
– –
MRUS
10
DELISTED
Merus
MRUS
$22.6M 4.41%
1,226,214
– –
CELC icon
11
Celcuity
CELC
$4.21B
$21.6M 4.21%
2,105,386
– –
JBIO
12
Jade Biosciences
JBIO
$1.2B
$16.8M 3.28%
23,826
+2,458
+12% +$2.04M
CABA icon
13
Cabaletta Bio
CABA
$437M
$16.3M 3.19%
1,973,251
+77,966
+4% +$730K
VECT
14
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$15.9M 3.1%
1,866,000
– –
ANNX icon
15
Annexon
ANNX
$834M
$12.4M 2.42%
3,220,050
– –
SVRA icon
16
Savara
SVRA
$1.12B
$12.4M 2.42%
6,351,531
– –
MIST icon
17
Milestone Pharmaceuticals
MIST
$138M
$8.7M 1.7%
2,208,812
– –
ACRS icon
18
Aclaris Therapeutics
ACRS
$726M
$8.42M 1.64%
1,040,754
-3,523,208
-77% -$44.7M
THRX
19
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$6.84M 1.34%
+770,000
New +$7.56M
TRVI icon
20
Trevi Therapeutics
TRVI
$2.59B
$5.64M 1.1%
3,050,022
– –
FULC icon
21
Fulcrum Therapeutics
FULC
$273M
$3.73M 0.73%
1,307,094
+859,768
+192% +$7.7M
LYRA
22
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.86M 0.36%
18,483
– –
AVTX icon
23
Avalo Therapeutics
AVTX
$965M
$1.75M 0.34%
+4,167
New +$3.28M
RLYB icon
24
Rallybio
RLYB
$84.5M
$1.53M 0.3%
33,567
– –
AFMD
25
DELISTED
Affimed
AFMD
$1.07M 0.21%
142,857
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2023 Portfolio in Review

As of Q1 2023, VR Adviser held 32 positions worth $512M, down 14% from $594M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

VR Adviser withdrew a net $45M in Q1 2023, closing 7 positions and reducing 2 holdings. Its most notable exit was Axsome Therapeutics, an estimated $51.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, VR Adviser opened a new position in Enliven Therapeutics worth $48.5M.

  • VR Adviser's largest Q1 2023 buy was Enliven Therapeutics: 2,214,142 shares worth $48.5M.
  • VR Adviser added most to Cogent Biosciences in Q1 2023, an estimated $10.8M increase.
  • VR Adviser's biggest Q1 2023 reduction was Aclaris Therapeutics, cutting an estimated $44.7M.
  • VR Adviser fully exited Axsome Therapeutics in Q1 2023, selling an estimated $51.7M.
  • VR Adviser's ten largest holdings make up 74% of its $512M portfolio in Q1 2023.
  • VR Adviser opened 4 new positions and closed 7 in Q1 2023.
  • VR Adviser's portfolio value fell 14% quarter-over-quarter to $512M.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.